Warchal Scott J, Unciti-Broceta Asier, Carragher Neil O
Cancer Research UK Edinburgh Centre, Institute of Genetics & Molecular Medicine, University of Edinburgh, Crewe Road South, Edinburgh EH4 2XR, UK.
Future Med Chem. 2016 Jul;8(11):1331-47. doi: 10.4155/fmc-2016-0025. Epub 2016 Jun 30.
Phenotypic drug discovery (PDD) strategies are defined by screening and selection of hit or lead compounds based on quantifiable phenotypic endpoints without prior knowledge of the drug target. We outline the challenges associated with traditional phenotypic screening strategies and propose solutions and new opportunities to be gained by adopting modern PDD technologies. We highlight both historical and recent examples of approved drugs and new drug candidates discovered by modern phenotypic screening. Finally, we offer a prospective view of a new era of PDD underpinned by a wealth of technology advances in the areas of in vitro model development, high-content imaging and image informatics, mechanism-of-action profiling and target deconvolution.
表型药物发现(PDD)策略的定义是,在不预先了解药物靶点的情况下,基于可量化的表型终点筛选和选择活性化合物或先导化合物。我们概述了传统表型筛选策略所面临的挑战,并提出了采用现代PDD技术可获得的解决方案和新机遇。我们重点介绍了通过现代表型筛选发现的已批准药物和新药候选物的历史及近期实例。最后,我们展望了PDD新时代的前景,这一新时代将受益于体外模型开发、高内涵成像和图像信息学、作用机制分析及靶点反卷积等领域的大量技术进步。